Objectives. To assess the dynamics of cognitive impairment (CI) in patients with Parkinson’s disease (PD) during L-DOPA treatment. Materials and methods. A randomized clinical trial included 41 patients with confirmed diagnoses of PD at stage 2.5–3.5 on the Hoehn and Yahr scale, mainly of the akinetic-rigid and mixed forms, who were taking levodopa and had PD-associated CI syndrome. Mean duration of illness was five years. The design included randomization of study participants to two groups. The dynamics of CI were assessed using neuropsychological investigations on two occasions separated by six months: group 1 in the on and off phases of L-DOPA therapy and group 2 in the off and on phases of levodopa therapy, respectively. The state of CI was assessed on the Mini Mental State Examination (MMSE), the Montreal Cognitive Assessment Scale (MoCA), the Frontal Assessment Battery (FAB), the Scales for Outcomes in Parkinson’s Disease – Cognition (SCOPA-Cog), and the Geriatric Depression Scale (GDS). Results. A statistically significant improvement in cognitive status was seen at the on phase of levodopa action, along with degradation in the off phase of L-DOPA therapy in the form of increased cognitive deficit (p < 0.05). Conclusions. CI in PD may to some extent be dependent on L-DOPA therapy, as well as on motor signs. The most dynamic functions on the background of L-DOPA therapy were attention, language, and executive and visuospatial functions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
T. Pringsheim, N. Jette, A. Frolkis, and T. D. Steeves, “The prevalence of Parkinson’s disease: a systematic review and meta-analysis,” Mov. Disord., 29, 1583–1590 (2014), https://doi.org/10.1002/mds.25244.
A. B. Singleton, M. J. Farrer, and V. Bonifati, “The genetics of Parkinson’s disease: progress and therapeutic implications,” Mov. Disord., 28, 14–23 (2013), https://doi.org/10.1007/978-3-319-17223-1_2.
O. S. Levin and L. V. Dokadina, “Epidemiology of parkinsonism and Parkinson’s disease,” Nevrol. Zh., 10, No. 5, 41–49 (2005), https://www.elibrary.ru/ip_restricted.asp?rpage=https%3A%2F%2Fwww%2Eelibrary%2Eru%2Fitem%2Easp%3Fid%3D9136241.
B. Pascual-Sedano, J. Kulisevsky, M. Barbanoj, et al., “Levodopa and executive performance in Parkinson’s disease: A randomized study,” J. Int. Neuropsychol. Sol., 14, No. 5, 832–841 (2008), https://doi.org/10.1017/S1355617708081010.
K. W. Lange, T. W. Robbins, C. D. Marsden, et al., “L-dopa withdrawal in Parkinson’s disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction,” Psychopharmacology, 107, 394–404 (1992), https://doi.org/10.1007/bf02245167.
S. J. G. Lewis, A. Slabosz, T. W. Robbins, et al., “Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson’s Disease,” Neuropsychology, 43, 823–832 (2005), https://doi.org/10.1016/j.neuropsychologia.2004.10.001.
D. W. Dickson, H. Braak, J. E. Duda, et al., “Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria,” Lancet Neurol., 8, 1150–1157 (2009), https://doi.org/10.1016/s1474-4422(09)70238-8.
K. R. Chaudhuri and A. H. Schapira, “Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment,” Lancet Neurol., 8, 464–474 (2009), https://doi.org/10.1016/S1474-4422(09)70068-7.
N. V. Titova and K. R. Chauduri, “Non-motor symptoms of Parkinson’s disease: the submerged part of the iceberg,” Ann. Klin. Eksperim. Nevrol., 11, No. 4, 5–18 (2017), https://cyberleninka.ru/article/n/nemotornye-simptomy-bolezni-parkinsona-podvodnaya-chast-aysberga.
S. Borson, J. M. Scanlan, and P. J. Chen, “The Mini-Cog as a screen for dementia: Validation in a population-based Sample,” J. Am. Ger. Soc., 51, 1451–1454 (2003), https://doi.org/10.1046/j.1532-5415.2003.51465.x.
O. S. Levin, Diagnosis and Treatment of Dementia in Clinical Practice, MEDpress-Inform, Moscow (2012).
A. Busse, J. Bischkopf, and S. D. Riedel-Heller, “Mild cognitive impairment: prevalence and incidence according to different diagnostic criteria,” Brit. J. Psychiatry, 182, 449–454 (2003), https://doi.org/10.1192/bjp.182.5.449.
M. F. Folstein, S. E. Folstein, and P. R. McHugh, “Mini-Mental State,” J. Psychiatr. Res., 12, 189–198 (1975), https://doi.org/10.1016/0022-3956(75)90026-6.
S. T. Pendlebury, J. Mariz, and L. Bull, “MoCA, ACE-R, and MMSE Versus the National Institute of Neurological Disorders and Stroke-Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards Neuropsychological Battery after TIA and Stroke,” Stroke, 43, No. 2, 464–469 (2012), https://doi.org/10.1161/strokeaha.111.633586.
A. Slachevsky, J. M. Villalpando, and M. Sarazin, “Frontal assessment battery and differential diagnosis of frontotemporal dementia and Alzheimer disease,” Arch. Neurol., 61, No. 7, 1104–1107 (2004), https://doi.org/10.1001/archneur.61.7.1104.
J. Marinus, M. Visser, N. A. Verwey, et al., “Assessment of cognition in Parkinson’s disease,” Neurology, 61, No. 9, 122–1228 (2003), https://doi.org/10.1212/01.wnl.0000091864.39702.1c.
J. A. Yesavage, T. L. Brink, T. L. Rose, et al., “Development and validation of a geriatric depression screening scale: A preliminary report,” J. Psychiatr. Res., 17, 37–49 (1982), https://doi.org/10.1016/0022-3956(82)90033-4.
G. G. Avtandilov and G. G. “Medial Morphometry. Guidelines, Meditsina, Moscow (1990).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 121, No. 7, Iss. 1, pp. 36–41, July, 2021.
Rights and permissions
About this article
Cite this article
Ismailova, S.B., Prokopenko, S.V., Pokhabov, D.V. et al. Dynamics of Cognitive Impairments in Patients with Parkinson’s Disease Receiving L-DOPA Treatment. Neurosci Behav Physi 52, 368–372 (2022). https://doi.org/10.1007/s11055-022-01250-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11055-022-01250-2